Anavex Life Sciences Achieves Milestone in Parkinson’s Disease Treatment
Anavex Life Sciences has reported promising results from its 48-week Phase 2 extension study, marking a significant advancement in Parkinson’s disease treatment. The study focused on the efficacy of ANAVEX®2-73 (blarcamesine), a groundbreaking small-molecule drug aimed at neurodegenerative and neurodevelopmental disorders. Across the board, patients receiving ANAVEX®2-73 delivered improved outcomes in all efficacy endpoints. Notably,…